2024-04-25-深交所-新华制药_2024年一季度报告_10页_442kb

Financial Performance

• Revenue for Q1 2024 was 2,474,697,457.66 yuan, a -6.25% decrease compared to Q1 2023.
• Net profit attributable to shareholders was 141,879,437.62 yuan, down -6.41%.
• Net profit excluding non-recurring items decreased -6.41%.
• Cash flow from operations improved to 38,063,364.43 yuan, an increase of +120.72% versus a net loss in Q1 2023.
• Basic earnings per share (EPS) was 0.21 yuan, a -8.70% drop from 0.23 yuan in the same period last year.
• Weighted average净资产收益率 (ROE) was 3.04%, down from 3.59%.

Shareholder Information

• Total ordinary shareholders increased to 89,701, with state-owned entities dominating the shareholding structure.
• Key shareholders include:
  • 华鲁控股集团有限公司 with 30.02% stake.
  • 香港中央结算（代理人）有限公司 with 28.33%.
  • 华鲁投资发展有限公司 with 5.44%.
• Top individual shareholders include 于海涛, 胡魁, and others holding small percentages.

Significant Events

• On January 2, 2024, adjustments were made to the 2021 A-shares stock option incentive plan, including changes to stock prices and option grants.
• 772.48 million options became exercisable in the first tranche, with associated corporate actions documented.